ClinVar Miner

Submissions for variant NM_001904.4(CTNNB1):c.1420C>T (p.Arg474Ter)

dbSNP: rs1553631860
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CeGaT Center for Human Genetics Tuebingen RCV001092247 SCV001248662 pathogenic not provided 2019-11-01 criteria provided, single submitter clinical testing
Diagnostic Laboratory, Strasbourg University Hospital RCV001260750 SCV001437842 pathogenic Intellectual disability 2020-09-10 criteria provided, single submitter clinical testing
Laboratory of Molecular Genetics (Pr. Bezieau's lab), CHU de Nantes RCV001374918 SCV001572205 pathogenic Neurodevelopmental disorder 2021-02-24 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV001092247 SCV001585620 pathogenic not provided 2024-12-03 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg474*) in the CTNNB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNNB1 are known to be pathogenic (PMID: 23033978, 24614104, 25326669, 26350204, 28575650). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of CTNNB1-related conditions (PMID: 25326669, 27915094, 28333917). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 559636). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV001092247 SCV001793852 pathogenic not provided 2022-10-13 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28333917, 34758253, 27915094, 25326669, 27479843, 29786110, 31785789, 33004838)
3billion, Medical Genetics RCV000677408 SCV002059042 pathogenic Severe intellectual disability-progressive spastic diplegia syndrome 2022-01-03 criteria provided, single submitter clinical testing The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000559636, PMID:25326669). Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). It is not observed in the gnomAD v2.1.1 dataset (PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.
Laboratory of Medical Genetics, National & Kapodistrian University of Athens RCV002286777 SCV002577572 pathogenic Microcephalic primordial dwarfism, Alazami type 2022-02-28 criteria provided, single submitter clinical testing PVS1, PM2, PP3, PP5
MGZ Medical Genetics Center RCV000677408 SCV002579785 pathogenic Severe intellectual disability-progressive spastic diplegia syndrome 2021-12-10 criteria provided, single submitter clinical testing
Department of Genetics, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine RCV003126902 SCV003803831 pathogenic Developmental disorder 2022-01-04 criteria provided, single submitter clinical testing
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV000677408 SCV003807448 pathogenic Severe intellectual disability-progressive spastic diplegia syndrome 2022-03-17 criteria provided, single submitter clinical testing ACMG classification criteria: PVS1 very strong, PS4 moderated, PM2 moderated, PM6 moderated
Molecular Genetics Lab, CHRU Brest RCV003883158 SCV004697623 pathogenic Medulloblastoma; Pilomatrixoma; Ovarian neoplasm; Severe intellectual disability-progressive spastic diplegia syndrome; Hepatocellular carcinoma; Colorectal cancer; Exudative vitreoretinopathy 7 criteria provided, single submitter clinical testing
Molecular Genetics Laboratory, BC Children's and BC Women's Hospitals RCV000677408 SCV000803712 pathogenic Severe intellectual disability-progressive spastic diplegia syndrome 2018-03-07 no assertion criteria provided clinical testing
Genomics England Pilot Project, Genomics England RCV000677408 SCV001760123 pathogenic Severe intellectual disability-progressive spastic diplegia syndrome no assertion criteria provided clinical testing
Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India RCV000677408 SCV002318925 pathogenic Severe intellectual disability-progressive spastic diplegia syndrome no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.